• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EVP and CFO Eldessouky Sam was granted 42,517 shares, increasing direct ownership by 15% to 320,816 units (SEC Form 4)

    8/7/25 4:46:53 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Eldessouky Sam

    (Last) (First) (Middle)
    C/O BAUSCH + LOMB CORPORATION
    520 APPLEWOOD CRESCENT

    (Street)
    VAUGHAN A6 L4K 4B4

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Bausch & Lomb Corp [ BLCO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP and CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    08/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Shares, No Par Value 08/05/2025 A 42,517(1) A $0 320,816 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on March 1, 2023 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2025. The earned PSUs will vest on March 1, 2026, subject generally to the reporting person's continued employment through such date.
    /s/ Debra E. Levin, attorney-in-fact 08/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BLCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    1/5/2026$18.00Outperform → In-line
    Evercore ISI
    12/11/2025$20.00Neutral → Buy
    Citigroup
    12/2/2025$21.00Equal-Weight → Overweight
    Morgan Stanley
    10/1/2025$16.00Neutral
    Goldman
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bausch + Lomb downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00

    1/5/26 8:46:17 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Citigroup with a new price target

    Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00

    12/11/25 8:44:49 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00

    12/2/25 8:17:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Collis Steven H

    3 - Bausch & Lomb Corp (0001860742) (Issuer)

    1/9/26 6:39:51 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Alfonso Eduardo

    3 - Bausch & Lomb Corp (0001860742) (Issuer)

    1/9/26 6:06:45 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Robertson Russel C was granted 1,642 shares, increasing direct ownership by 3% to 66,556 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    11/18/25 4:42:57 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/27/25 8:16:24 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/6/25 4:30:10 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/24 5:29:48 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    SEC Filings

    View All

    Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    1/2/26 4:10:34 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Amendment: Bausch + Lomb Corporation filed SEC Form 8-K: Leadership Update

    8-K/A - Bausch & Lomb Corp (0001860742) (Filer)

    12/22/25 4:10:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by Bausch + Lomb Corporation

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    12/17/25 4:44:26 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

    Bausch + Lomb to launch fifth annual fundraising challenge during Glaucoma Awareness Month in partnership with Glaucoma Research Foundation, with all proceeds supporting glaucoma research Bausch + Lomb will also sponsor The Glaucoma Foundation's annual month-long educational social media campaign, which spotlights stories from glaucoma patients and advocates Glaucoma affects about four million people in the United States1 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundation (GRF) during Glaucoma Awareness Month in Ja

    1/5/26 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously announced credit agreement refinancing. In connection with the closing, Bausch + Lomb has entered into a fourth amendment (the "Fourth Amendment") to its existing credit agreement providing for a $2,802,125,000 tranche (the "Replacement Term Loans") of new term B loans, the proceeds of which were used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans") and its outstanding term B loans due 2028 (the "First Incremental Term Loans"). The am

    1/2/26 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET). A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website: http://ir.bausch.com/investors/events-presentations. About Bausch + Lomb Our miss

    12/23/25 7:30:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Announces Third-Quarter 2025 Results

    Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con

    10/29/25 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 29, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its product pipeline which features potential game-changing innovations in each business unit. T

    9/29/25 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Second-Quarter 2025 Results

    Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP)1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $192 Million Revenue Grew 5% as Reported and 3% on a Constant Currency1 Basis Compared to the Second Quarter of 2024, which Absorbs the enVista® Intraocular Lenses Voluntary Recall Raising Full-Year 2025 Guidance to Reflect Solid Business Performance and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. "Our con

    7/30/25 6:57:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care